What cardiovascular complications can patients with primary adrenal insufficiency on mineralocorticoid replacement develop?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Cardiovascular Complications in Primary Adrenal Insufficiency on Mineralocorticoid Replacement

Patients with primary adrenal insufficiency on mineralocorticoid replacement can develop hypertension, peripheral edema, and paradoxically may also experience features of chronic hypovolemia including postural hypotension, smaller cardiac chamber sizes, and increased cardiovascular mortality despite treatment. 1

Primary Cardiovascular Problems

Hypertension from Over-Replacement

Essential hypertension can develop in PAI patients and should be treated by adding a vasodilator, not by stopping mineralocorticoid replacement, although dose reduction should be considered. 1 The guidelines are explicit that fludrocortisone should not be discontinued even when hypertension develops—instead, add antihypertensive therapy while potentially reducing the mineralocorticoid dose.

  • Preferred antihypertensives: Angiotensin II receptor blockers or ACE inhibitors to counter vasoconstrictive effects 2
  • Second-line: Dihydropyridine calcium channel blockers 2
  • Avoid completely: Diuretics, acetazolamide, aldosterone receptor blockers (spironolactone, eplerenone) 1, 2

Hypovolemia-Related Cardiovascular Changes

Despite mineralocorticoid replacement, patients frequently exhibit cardiovascular features consistent with chronic hypovolemia 3:

  • Smaller left ventricular diastolic diameter (47.1 vs 51.6 mm in controls, p=0.001)
  • Smaller left atrial diameter (34.9 vs 38.2 cm in controls, p=0.018)
  • Higher ejection fraction (62.5% vs 56.0%, p=0.003)—a compensatory response to reduced preload
  • Lower nocturnal blood pressure (systolic 108 vs 117 mmHg, p=0.038; diastolic 65 vs 73 mmHg, p=0.008)

This suggests that mineralocorticoid under-replacement is common and often unrecognized 1, 4, sometimes compensated for by glucocorticoid over-replacement.

Life-Threatening Cardiovascular Complications

Cardiomyopathy

Adrenal insufficiency can cause reversible dilated cardiomyopathy, takotsubo cardiomyopathy, and congestive heart failure 5, 6. These complications can occur with all forms of AI and improve rapidly with appropriate hormone replacement. One case demonstrated complete recovery of biventricular dysfunction and severe tricuspid regurgitation within one month of initiating hydrocortisone therapy 6.

Arrhythmias and Circulatory Collapse

  • Lethal arrhythmias
  • Supraventricular tachycardia
  • Bradycardia
  • Circulatory failure and shock 5

Increased Long-Term Cardiovascular Risk

Patients with PAI have excess cardiovascular mortality despite adequate replacement therapy 7, 8. A 2025 study found that 298 of 327 AI patients (91%) had one or more cardiovascular risk factors, with inadequate monitoring and treatment 7:

  • Arterial hypertension: 91 patients diagnosed, but 44% still had elevated BP despite treatment
  • Hyperlipoproteinemia: Only 2% achieved normal lipid values across all parameters; 46% had at least one untested lipid variable
  • Diabetes: 25% of diabetic patients had elevated HbA1c
  • Obesity: 25% of patients had no BMI measurements documented

Unique RAAS Abnormalities

Despite fludrocortisone replacement, the renin-angiotensin-aldosterone system remains hyperactivated 8:

  • Profoundly elevated renin, angiotensin I, angiotensin II (the potent vasoconstrictor), angiotensin 1-7, and angiotensin 1-5
  • Absent or undetectable aldosterone despite elevated angiotensin metabolites
  • Suppressed aldosterone-to-angiotensin II ratio (p=0.003)

This persistent RAAS hyperactivation may contribute to increased cardiovascular disease despite state-of-the-art hormone replacement.

Critical Clinical Pitfalls

Under-Replacement is Common

Mineralocorticoid under-replacement is frequently missed and may predispose to recurrent adrenal crises 1. Signs include:

  • Salt craving
  • Postural dizziness/lightheadedness
  • Postural hypotension
  • Hyponatremia
  • Hyperkalemia
  • Elevated plasma renin activity

Monitor mineralocorticoid adequacy by: Clinical symptoms, blood pressure (supine and standing), peripheral edema assessment, serum electrolytes, and plasma renin activity in the upper normal range 1, 9, 2.

Drug Interactions Affecting Cardiovascular Risk

Avoid these medications as they interact with fludrocortisone 1:

  • NSAIDs
  • Licorice and grapefruit juice (potentiate mineralocorticoid effect)
  • Drospirenone-containing contraceptives (may require increased fludrocortisone)

Compensatory Glucocorticoid Over-Replacement

Inadequate mineralocorticoid replacement is sometimes compensated by glucocorticoid over-replacement 1, which itself contributes to cardiovascular risk through metabolic effects including central obesity, hyperglycemia, and dyslipidemia.

References

4
Research

Primary Adrenal Insufficiency: Managing Mineralocorticoid Replacement Therapy.

The Journal of clinical endocrinology and metabolism, 2018

Related Questions

What does a normal DHEA level indicate in a patient with elevated plasma renin activity and a low aldosterone-to-renin ratio?
In a patient taking Gatorlyte who presents with elevated cortisol, dyslipidemia (high total cholesterol, LDL, triglycerides, low HDL), elevated hepatic transaminases, and sinus tachycardia, what is the appropriate pharmacologic management, including treatment for cortisol excess, lipid abnormalities, tachycardia, and the role of antibiotics?
What are the causes of secondary and tertiary adrenal insufficiency?
Does a low diastolic blood pressure indicate hypovolemia (low circulating blood volume)?
What is the recommended monitoring plan for a patient with adrenal insufficiency receiving glucocorticoid and mineralocorticoid replacement?
In a child receiving azithromycin (intravenous) 10 mg/kg once daily, can the dose be administered 2–4 hours earlier or later than the scheduled time?
In a patient with type 2 diabetes who has no cardiovascular disease, no renal impairment, and normal renal function, what does the recent American Diabetes Association (ADA) guideline recommend regarding the use of sodium‑glucose co‑transporter‑2 (SGLT2) inhibitors?
Can I support the treatment of chronic bacterial prostatitis?
What are the appropriate next steps in management for an 8‑cm renal cyst identified on ultrasound?
When should synovial fluid adenosine deaminase (ADA) be measured and what level indicates tuberculous arthritis?
In a patient without comorbidities, which medication should be added after metformin according to the latest American Diabetes Association (ADA) guidelines?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.